Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

CRISPR-induced double-strand breaks trigger recombination between homologous chromosome arms.

Brunner E, Yagi R, Debrunner M, Beck-Schneider D, Burger A, Escher E, Mosimann C, Hausmann G, Basler K.

Life Sci Alliance. 2019 Jun 13;2(3). pii: e201800267. doi: 10.26508/lsa.201800267. Print 2019 Jun.

2.

Angiotensin II cyclic analogs as tools to investigate AT1R biased signaling mechanisms.

St-Pierre D, Cabana J, Holleran BJ, Besserer-Offroy É, Escher E, Guillemette G, Lavigne P, Leduc R.

Biochem Pharmacol. 2018 Aug;154:104-117. doi: 10.1016/j.bcp.2018.04.021. Epub 2018 Apr 20.

PMID:
29684376
3.

Design, synthesis, and biological evaluation of CXCR4 ligands.

Mona CE, Besserer-Offroy É, Cabana J, Leduc R, Lavigne P, Heveker N, Marsault É, Escher E.

Org Biomol Chem. 2016 Nov 2;14(43):10298-10311.

PMID:
27752700
4.

Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists.

Mona CE, Besserer-Offroy É, Cabana J, Lefrançois M, Boulais PE, Lefebvre MR, Leduc R, Lavigne P, Heveker N, Marsault É, Escher E.

J Med Chem. 2016 Aug 25;59(16):7512-24. doi: 10.1021/acs.jmedchem.6b00566. Epub 2016 Aug 11.

PMID:
27434274
5.

Identification of Distinct Conformations of the Angiotensin-II Type 1 Receptor Associated with the Gq/11 Protein Pathway and the β-Arrestin Pathway Using Molecular Dynamics Simulations.

Cabana J, Holleran B, Leduc R, Escher E, Guillemette G, Lavigne P.

J Biol Chem. 2015 Jun 19;290(25):15835-54. doi: 10.1074/jbc.M114.627356. Epub 2015 May 1.

6.

Characterization of Angiotensin II Molecular Determinants Involved in AT1 Receptor Functional Selectivity.

Domazet I, Holleran BJ, Richard A, Vandenberghe C, Lavigne P, Escher E, Leduc R, Guillemette G.

Mol Pharmacol. 2015 Jun;87(6):982-95. doi: 10.1124/mol.114.097337. Epub 2015 Mar 25.

PMID:
25808928
7.

Identification of transmembrane domain 1 & 2 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor.

Sainsily X, Cabana J, Holleran BJ, Escher E, Lavigne P, Leduc R.

Biochem Pharmacol. 2014 Nov 15;92(2):280-8. doi: 10.1016/j.bcp.2014.08.023. Epub 2014 Aug 29.

PMID:
25175740
8.

Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor.

Sainsily X, Cabana J, Boulais PE, Holleran BJ, Escher E, Lavigne P, Leduc R.

Biochem Pharmacol. 2013 Dec 1;86(11):1584-93. doi: 10.1016/j.bcp.2013.09.015. Epub 2013 Sep 29.

PMID:
24084430
9.

Manipulating the sensitivity of signal-induced repression: quantification and consequences of altered brinker gradients.

Gafner L, Dalessi S, Escher E, Pyrowolakis G, Bergmann S, Basler K.

PLoS One. 2013 Aug 8;8(8):e71224. doi: 10.1371/journal.pone.0071224. eCollection 2013.

10.

Intestinal parasite prevalence in an area of ethiopia after implementing the SAFE strategy, enhanced outreach services, and health extension program.

King JD, Endeshaw T, Escher E, Alemtaye G, Melaku S, Gelaye W, Worku A, Adugna M, Melak B, Teferi T, Zerihun M, Gesese D, Tadesse Z, Mosher AW, Odermatt P, Utzinger J, Marti H, Ngondi J, Hopkins DR, Emerson PM.

PLoS Negl Trop Dis. 2013 Jun 6;7(6):e2223. doi: 10.1371/journal.pntd.0002223. Print 2013.

11.

Structure of the human angiotensin II type 1 (AT1) receptor bound to angiotensin II from multiple chemoselective photoprobe contacts reveals a unique peptide binding mode.

Fillion D, Cabana J, Guillemette G, Leduc R, Lavigne P, Escher E.

J Biol Chem. 2013 Mar 22;288(12):8187-97. doi: 10.1074/jbc.M112.442053. Epub 2013 Feb 5.

12.

Critical hydrogen bond formation for activation of the angiotensin II type 1 receptor.

Cabana J, Holleran B, Beaulieu MÈ, Leduc R, Escher E, Guillemette G, Lavigne P.

J Biol Chem. 2013 Jan 25;288(4):2593-604. doi: 10.1074/jbc.M112.395939. Epub 2012 Dec 7.

13.

Analysis by substituted cysteine scanning mutagenesis of the fourth transmembrane domain of the CXCR4 receptor in its inactive and active state.

Boulais PE, Escher E, Leduc R.

Biochem Pharmacol. 2013 Feb 15;85(4):541-50. doi: 10.1016/j.bcp.2012.11.022. Epub 2012 Dec 5.

PMID:
23219524
14.

Differential β-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs.

Zimmerman B, Beautrait A, Aguila B, Charles R, Escher E, Claing A, Bouvier M, Laporte SA.

Sci Signal. 2012 Apr 24;5(221):ra33. doi: 10.1126/scisignal.2002522.

15.

Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin binding site.

Wangler NJ, Santos KL, Schadock I, Hagen FK, Escher E, Bader M, Speth RC, Karamyan VT.

J Biol Chem. 2012 Jan 2;287(1):114-22. doi: 10.1074/jbc.M111.273052. Epub 2011 Oct 28.

16.

Agonists for the Chemokine Receptor CXCR4.

Lefrançois M, Lefebvre MR, Saint-Onge G, Boulais PE, Lamothe S, Leduc R, Lavigne P, Heveker N, Escher E.

ACS Med Chem Lett. 2011 Aug 11;2(8):597-602. Epub 2011 Jun 6.

17.

Preliminary biochemical characterization of the novel, non-AT1, non-AT2 angiotensin binding site from the rat brain.

Karamyan VT, Arsenault J, Escher E, Speth RC.

Endocrine. 2010 Jun;37(3):442-8. doi: 10.1007/s12020-010-9328-2. Epub 2010 Apr 13. Erratum in: Endocrine. 2010 Oct;38(2):312.

18.

Temperature dependent photolabeling of the human angiotensin II type 1 receptor reveals insights into its conformational landscape and its activation mechanism.

Arsenault J, Cabana J, Fillion D, Leduc R, Guillemette G, Lavigne P, Escher E.

Biochem Pharmacol. 2010 Oct 1;80(7):990-9. doi: 10.1016/j.bcp.2010.06.004. Epub 2010 Jun 19.

PMID:
20599798
19.

GPR103b functions in the peripheral regulation of adipogenesis.

Mulumba M, Jossart C, Granata R, Gallo D, Escher E, Ghigo E, Servant MJ, Marleau S, Ong H.

Mol Endocrinol. 2010 Aug;24(8):1615-25. doi: 10.1210/me.2010-0010. Epub 2010 Jun 9.

20.

A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.

Arsenault J, Lehoux J, Lanthier L, Cabana J, Guillemette G, Lavigne P, Leduc R, Escher E.

Pharmacogenet Genomics. 2010 Jun;20(6):377-88. doi: 10.1097/FPC.0b013e32833a6d4a.

PMID:
20436376
21.

The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1.

Fillion D, Lemieux G, Basambombo LL, Lavigne P, Guillemette G, Leduc R, Escher E.

J Med Chem. 2010 Mar 11;53(5):2063-75. doi: 10.1021/jm9015747.

PMID:
20146480
22.

Analysis of transmembrane domains 1 and 4 of the human angiotensin II AT1 receptor by cysteine-scanning mutagenesis.

Yan L, Holleran BJ, Lavigne P, Escher E, Guillemette G, Leduc R.

J Biol Chem. 2010 Jan 22;285(4):2284-93. doi: 10.1074/jbc.M109.077180. Epub 2009 Nov 23.

23.

The fifth transmembrane domain of angiotensin II Type 1 receptor participates in the formation of the ligand-binding pocket and undergoes a counterclockwise rotation upon receptor activation.

Domazet I, Martin SS, Holleran BJ, Morin ME, Lacasse P, Lavigne P, Escher E, Leduc R, Guillemette G.

J Biol Chem. 2009 Nov 13;284(46):31953-61. doi: 10.1074/jbc.M109.051839. Epub 2009 Sep 22.

24.

Activation induces structural changes in the liganded angiotensin II type 1 receptor.

Clément M, Cabana J, Holleran BJ, Leduc R, Guillemette G, Lavigne P, Escher E.

J Biol Chem. 2009 Sep 25;284(39):26603-12. doi: 10.1074/jbc.M109.012922. Epub 2009 Jul 27.

25.

Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site.

Boulais PE, Dulude D, Cabana J, Heveker N, Escher E, Lavigne P, Leduc R.

Biochem Pharmacol. 2009 Dec 1;78(11):1382-90. doi: 10.1016/j.bcp.2009.07.007. Epub 2009 Jul 22.

PMID:
19631193
26.

Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor.

Holleran BJ, Domazet I, Beaulieu ME, Yan LP, Guillemette G, Lavigne P, Escher E, Leduc R.

Biochem Pharmacol. 2009 Apr 15;77(8):1374-82. doi: 10.1016/j.bcp.2009.01.013. Epub 2009 Jan 29.

PMID:
19426676
27.

Monitoring of MMPs activity in vivo, non-invasively, using solubility switchable MRI contrast agent.

Jastrzebska B, Lebel R, McIntyre OJ, Paquette B, Neugebauer W, Escher E, Lepage M.

Adv Exp Med Biol. 2009;611:453-4. No abstract available.

PMID:
19400263
28.

Monitoring of native chemical ligation by surface plasmon resonance.

Wieczerzak E, Hame R Jr, Chabot V, Aimez V, Charette PG, Grandbois M, Escher E.

Adv Exp Med Biol. 2009;611:427-9. No abstract available.

PMID:
19400251
29.

Structural changes in the binding pocket of the liganded angiotensin II receptor AT1 during activation.

Clément M, Guillemette G, Leduc R, Escher E.

Adv Exp Med Biol. 2009;611:341-2. No abstract available.

PMID:
19400219
30.

Temperature-induced ligand contact point variations of the hAT1 receptor and of the constitutively active mutant N111G-hAT1.

Arsenault J, Renaud MP, Clément M, Fillion D, Guillemette G, Leduc R, Lavigne P, Escher E.

Adv Exp Med Biol. 2009;611:339-40. No abstract available.

PMID:
19400218
31.

Photoprobe peptides to map the interactions of angiotensin II with its receptor AT1.

Fillion D, Guillemette G, Leduc R, Escher E.

Adv Exp Med Biol. 2009;611:329-30. No abstract available.

PMID:
19400214
32.

The second transmembrane domain of the human type 1 angiotensin II receptor participates in the formation of the ligand binding pocket and undergoes integral pivoting movement during the process of receptor activation.

Domazet I, Holleran BJ, Martin SS, Lavigne P, Leduc R, Escher E, Guillemette G.

J Biol Chem. 2009 May 1;284(18):11922-9. doi: 10.1074/jbc.M808113200. Epub 2009 Mar 9.

33.

New enzyme-activated solubility-switchable contrast agent for magnetic resonance imaging: from synthesis to in vivo imaging.

Jastrzebska B, Lebel R, Therriault H, McIntyre JO, Escher E, Guérin B, Paquette B, Neugebauer WA, Lepage M.

J Med Chem. 2009 Mar 26;52(6):1576-81. doi: 10.1021/jm801411h.

PMID:
19228016
34.

Surface Plasmon Resonance Monitoring of Cell Monolayer Integrity: Implication of Signaling Pathways Involved in Actin-Driven Morphological Remodeling.

Cuerrier CM, Chabot V, Vigneux S, Aimez V, Escher E, Gobeil F, Charette PG, Grandbois M.

Cell Mol Bioeng. 2008 Dec 1;1(4):229-239.

35.

Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model.

Lebel R, Jastrzebska B, Therriault H, Cournoyer MM, McIntyre JO, Escher E, Neugebauer W, Paquette B, Lepage M.

Magn Reson Med. 2008 Nov;60(5):1056-65. doi: 10.1002/mrm.21741.

36.

Biosensing based on surface plasmon resonance and living cells.

Chabot V, Cuerrier CM, Escher E, Aimez V, Grandbois M, Charette PG.

Biosens Bioelectron. 2009 Feb 15;24(6):1667-73. doi: 10.1016/j.bios.2008.08.025. Epub 2008 Aug 26.

PMID:
18845432
37.

Mutational analysis of the conserved Asp2.50 and ERY motif reveals signaling bias of the urotensin II receptor.

Proulx CD, Holleran BJ, Boucard AA, Escher E, Guillemette G, Leduc R.

Mol Pharmacol. 2008 Sep;74(3):552-61. doi: 10.1124/mol.108.045054. Epub 2008 May 28.

PMID:
18509066
38.

Functional effects of caloxin 1c2, a novel engineered selective inhibitor of plasma membrane Ca(2+)-pump isoform 4, on coronary artery.

Pande J, Szewczyk MM, Kuszczak I, Grover S, Escher E, Grover AK.

J Cell Mol Med. 2008 Jun;12(3):1049-60. doi: 10.1111/j.1582-4934.2008.00140.x.

39.

Monitoring of native chemical ligation on solid substrate by surface plasmon resonance.

Wieczerzak E, Hamel R Jr, Chabot V, Aimez V, Grandbois M, Charette PG, Escher E.

Biopolymers. 2008;90(3):415-20. doi: 10.1002/bip.20945.

PMID:
18240142
40.

Biological properties and functional determinants of the urotensin II receptor.

Proulx CD, Holleran BJ, Lavigne P, Escher E, Guillemette G, Leduc R.

Peptides. 2008 May;29(5):691-9. Epub 2007 Nov 17. Review.

PMID:
18155322
41.

Ascorbic acid decreases the binding affinity of the AT1 receptor for angiotensin II.

Leclerc PC, Proulx CD, Arguin G, Bélanger S, Gobeil F Jr, Escher E, Leduc R, Guillemette G.

Am J Hypertens. 2008 Jan;21(1):67-71.

PMID:
18091746
42.

Temperature-dependent variations of ligand-receptor contact points in hAT(1).

Arsenault J, Renaud MP, Clément M, Fillion D, Guillemette G, Leduc R, Lavigne P, Escher E.

J Pept Sci. 2007 Sep;13(9):575-80.

PMID:
17600857
43.

Activation of the angiotensin II type 1 receptor leads to movement of the sixth transmembrane domain: analysis by the substituted cysteine accessibility method.

Martin SS, Holleran BJ, Escher E, Guillemette G, Leduc R.

Mol Pharmacol. 2007 Jul;72(1):182-90. Epub 2007 Apr 19.

PMID:
17446269
44.

Low-energy (3-24 eV) electron damage to the peptide backbone.

Cloutier P, Sicard-Roselli C, Escher E, Sanche L.

J Phys Chem B. 2007 Feb 22;111(7):1620-4. Epub 2007 Jan 26.

PMID:
17256896
45.

[The methionine proximity assay: an approach to glean receptor structures].

Clément M, Escher E.

Med Sci (Paris). 2006 Dec;22(12):1017-8. French. No abstract available.

46.
47.

The active and the inactive form of the hAT1 receptor have an identical ligand-binding environment: an MPA study on a constitutively active angiotensin II receptor mutant.

Clément M, Chamberland C, Pérodin J, Leduc R, Guillemette G, Escher E.

J Recept Signal Transduct Res. 2006;26(5-6):417-33.

PMID:
17118790
48.

Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.

Holleran BJ, Beaulieu ME, Proulx CD, Lavigne P, Escher E, Leduc R.

Biochem J. 2007 Feb 15;402(1):51-61.

50.

S-nitrosylation of cysteine 289 of the AT1 receptor decreases its binding affinity for angiotensin II.

Leclerc PC, Lanctot PM, Auger-Messier M, Escher E, Leduc R, Guillemette G.

Br J Pharmacol. 2006 Jun;148(3):306-13.

Supplemental Content

Loading ...
Support Center